Clinicopathologic Conference, Posterior Reversible Encephalopathy Syndrome Due to Sickle Cell Disease
NEJM 392:268-276, Case 2-2025, 2025
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021